Last reviewed · How we verify

Peptavlon (PENTAGASTRIN)

Wyeth Ayerst · FDA-approved approved Small molecule Quality 20/100

Peptavlon, also known as pentagastrin, is a small molecule drug that targets the gastrin/cholecystokinin type B receptor. Originally developed by Wyeth Ayerst, it was FDA approved in 1974 for certain indications. As an off-patent drug, there are currently no generic manufacturers. Peptavlon works by stimulating the gastrin/cholecystokinin type B receptor, which plays a role in gastric acid secretion. Its commercial status and key safety considerations are not well-documented.

At a glance

Generic namePENTAGASTRIN
SponsorWyeth Ayerst
Drug classpentagastrin
TargetGastrin/cholecystokinin type B receptor, Cholecystokinin receptor type A, Gastrin/cholecystokinin type B receptor
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved
First approval1974

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: